Payment overview · 2025
General Payments
$1,484.63
65 reported records · 24 companies
Healthcare provider profile · identity verified
Hugh D Durrence, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · CHARLESTON, SC · NPI 1750551206
Verified facts
What the public records show
CMS Open Payments records show Hugh D Durrence, M.D. received $1,484.63 in general payments during 2025 across 65 reported records.
Lilly USA, LLC accounted for 11.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 36 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $171.32 | 11.5% | 6 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $144.61 | 9.7% | 4 | 2025 |
| Averitas Pharma Inc. | Unresolved — no canonical attribution shown | $103.53 | 7.0% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $103.32 | 7.0% | 5 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $89.70 | 6.0% | 5 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $89.31 | 6.0% | 4 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $86.28 | 5.8% | 5 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $75.07 | 5.1% | 4 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $68.84 | 4.6% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $67.17 | 4.5% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $64.78 | 4.4% | 4 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $55.37 | 3.7% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $51.59 | 3.5% | 3 | 2025 |
| Noven Therapeutics, LLC | Unresolved — no canonical attribution shown | $45.88 | 3.1% | 2 | 2025 |
| CMS Imaging, Inc. | Unresolved — no canonical attribution shown | $43.08 | 2.9% | 1 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $41.73 | 2.8% | 2 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $35.05 | 2.4% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $30.10 | 2.0% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $24.52 | 1.6% | 1 | 2025 |
| Baxter Healthcare | Unresolved — no canonical attribution shown | $23.75 | 1.6% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $22.42 | 1.5% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $16.35 | 1.1% | 1 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $15.59 | 1.1% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $15.27 | 1.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,484.63 | 65 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $144.61 | 4 | 2025 |
Source payment records
|
|||||
| QUTENZA Normalized: qutenza |
Drug | Averitas Pharma Inc. | $103.53 | 2 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $86.28 | 5 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $75.07 | 4 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $68.84 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $66.39 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $66.39 | 4 | 2025 |
Source payment records
|
|||||
| ECC Solutions Normalized: ecc solutions |
Device | Philips North America LLC | $65.42 | 3 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $60.91 | 3 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $58.11 | 3 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $55.37 | 3 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $55.37 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $51.59 | 3 | 2025 |
Source payment records
|
|||||
| Xelstrym Normalized: xelstrym |
Drug | Noven Therapeutics, LLC | $45.88 | 2 | 2025 |
Source payment records
|
|||||
| SKYCLARYS Normalized: skyclarys |
Drug | Biogen, Inc. | $41.73 | 2 | 2025 |
Source payment records
|
|||||
| SAPIEN 3 Ultra RESILIA Normalized: sapien 3 ultra resilia |
Device | Edwards Lifesciences Corporation | $35.05 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $34.07 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $31.59 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $30.71 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $30.10 | 2 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $24.74 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $24.52 | 1 | 2025 |
Source payment records
|
|||||
| Ambulatory Monitoring & Diagnostics Undivided Normalized: ambulatory monitoring diagnostics undivided |
Device | Philips North America LLC | $23.89 | 1 | 2025 |
Source payment records
|
|||||
| Hillrom - RetinaVue 700 Imager Normalized: hillrom retinavue 700 imager |
Device | Baxter Healthcare | $23.75 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $23.17 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $22.42 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $18.66 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $18.66 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $18.08 | 1 | 2025 |
Source payment records
|
|||||
| AMS 700 Normalized: ams 700 |
Device | Boston Scientific Corporation | $16.35 | 1 | 2025 |
Source payment records
|
|||||
| BEYFORTUS Normalized: beyfortus |
Biological | SANOFI PASTEUR INC. | $15.59 | 1 | 2025 |
Source payment records
|
|||||
| FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE Normalized: flublok quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $15.59 | 1 | 2025 |
Source payment records
|
|||||
| FLUZONE HIGH-DOSE Normalized: fluzone high dose |
Biological | SANOFI PASTEUR INC. | $15.59 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $15.27 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $15.27 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $15.19 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
33 | 12 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 379 | 128 |
| Levothyroxine Sodium | Levothyroxine Sodium | 263 | 76 |
| Amlodipine Besylate | Amlodipine Besylate | 235 | 79 |
| Omeprazole | Omeprazole | 158 | 51 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 152 | 57 |
| Losartan Potassium | Losartan Potassium | 138 | 44 |
| Zolpidem Tartrate | Zolpidem Tartrate | 108 | 27 |
| Sertraline Hcl | Sertraline Hcl | 103 | 33 |
| Lisinopril | Lisinopril | 100 | 31 |
| Simvastatin | Simvastatin | 90 | 28 |
| Metformin Hcl | Metformin Hcl | 84 | 28 |
| Lorazepam | Lorazepam | 82 | 25 |
| Fluticasone Propionate | Fluticasone Propionate | 78 | 26 |
| Tamsulosin Hcl | Tamsulosin Hcl | 74 | 28 |
| Hydrochlorothiazide | Hydrochlorothiazide | 73 | 27 |
| Metformin Hcl Er | Metformin Hcl | 71 | 26 |
| Ezetimibe | Ezetimibe | 65 | 20 |
| Metoprolol Succinate | Metoprolol Succinate | 64 | 21 |
| Oxycodone Hcl | Oxycodone Hcl | 61 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 60 | 19 |
| Gabapentin | Gabapentin | 59 | 20 |
| Montelukast Sodium | Montelukast Sodium | 58 | 23 |
| Pravastatin Sodium | Pravastatin Sodium | 57 | 17 |
| Eliquis | Apixaban | 53 | 15 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 50 | 16 |
| Pantoprazole Sodium | Pantoprazole Sodium | 46 | 16 |
| Famotidine | Famotidine | 43 | 19 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 43 | 13 |
| Potassium Chloride | Potassium Chloride | 42 | 12 |
| Trazodone Hcl | Trazodone Hcl | 42 | 13 |
| Valsartan | Valsartan | 40 | 15 |
| Finasteride | Finasteride | 39 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 38 | 15 |
| Diazepam | Diazepam | 37 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 37 | 11 |
| Xarelto | Rivaroxaban | 37 | suppressed |
| Synthroid | Levothyroxine Sodium | 33 | 12 |
| Duloxetine Hcl | Duloxetine Hcl | 32 | 11 |
| Fenofibrate | Fenofibrate Nanocrystallized | 31 | suppressed |
| Alprazolam | Alprazolam | 30 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 29 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 29 | suppressed |
| Bupropion Xl | Bupropion Hcl | 28 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 28 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 28 | suppressed |
| Clonazepam | Clonazepam | 27 | suppressed |
| Atenolol | Atenolol | 26 | 11 |
| Chlorthalidone | Chlorthalidone | 26 | suppressed |
| Glipizide Er | Glipizide | 26 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 26 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 25 | 18 |
| Fluoxetine Hcl | Fluoxetine Hcl | 25 | suppressed |
| Furosemide | Furosemide | 25 | 13 |
| Jardiance | Empagliflozin | 25 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 25 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 24 | 11 |
| Mounjaro | Tirzepatide | 24 | suppressed |
| Ozempic | Semaglutide | 24 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 23 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 22 | suppressed |
| Celecoxib | Celecoxib | 22 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 22 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 22 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 22 | suppressed |
| Carvedilol | Carvedilol | 21 | suppressed |
| Myrbetriq | Mirabegron | 21 | suppressed |
| Testosterone | Testosterone | 19 | suppressed |
| Meloxicam | Meloxicam | 17 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 16 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 16 | suppressed |
| Trulicity | Dulaglutide | 16 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 16 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 15 | suppressed |
| Famciclovir | Famciclovir | 15 | suppressed |
| Fenofibrate | Fenofibrate | 15 | suppressed |
| Allopurinol | Allopurinol | 14 | suppressed |
| Spironolactone | Spironolactone | 14 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 13 | suppressed |
| Ramipril | Ramipril | 13 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 12 | suppressed |
| Gemtesa | Vibegron | 12 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 12 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 12 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 11 | suppressed |
| Estradiol | Estradiol | 11 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Victoza 3-Pak | Liraglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,484.63 · 65 records | Lilly USA, LLC | ACCRUFER, AIRSUPRA, AMS 700, Ambulatory Monitoring & Diagnostics Undivided, BEYFORTUS, CAPLYTA, CAPVAXIVE, Cologuard Collection Kit, Dexcom G6 Transmitter, ECC Solutions, FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE, FLUZONE HIGH-DOSE, FREESTYLE LIBRE 3, Fluad, Flucelvax, GARDASIL 9, Hillrom - RetinaVue 700 Imager, KISUNLA, Kerendia, MOUNJARO, Omnipod, Ozempic, QULIPTA, QUTENZA, Rybelsus, SAPIEN 3 Ultra RESILIA, SHINGRIX, SKYCLARYS, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, UBRELVY, VRAYLAR, Veozah, Wegovy, Xelstrym, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error